Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

actinium Ac 225 FPI-2059

A radioconjugate consisting of a neurotensin receptor type 1 (NTSR1)-targeting small molecule antagonist labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225 FPI-2059, the NTSR1-targeting moiety targets and binds to NTSR1 expressed on tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to NTSR1-expressing tumor cells. NTSR1, a G protein-coupled receptor for the tridecapeptide neurotensin (NTS), is overexpressed in certain types of cancers and plays a key role in tumor cell proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	[225Ac]-FPI-2059 225Ac-FPI-2059 Ac 225 FPI-2059

actinium Ac 225 FPI-2059

Search NCI's Drug Dictionary